Get started

Pharmaceuticals

VXRT was a top quarterly gainer, rising +376.19%. Expect UptrendVaxart (VXRT, $8) was one of top quarterly gainers, jumping +376.19% to $8 per share. Tickeron A.I.dvisor analyzed 174 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 155 of them (89.09%) charted an Uptrend while 19 of them (10.91%) trended down. Tickeron A.I.dvisor found 135 similar cases when VXRT's price went up 15% within three months. In 83 out of those 135 cases, VXRT's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for VXRT are 61%. VXRT in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on June 30, 2020 This price move signals that VXRT may fall back below the higher band and head toward the middle band. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 37 of 42 cases where VXRT's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 88%.
NASDAQ:VXRTShort
by AlTorress
GLENMARK 01 JULY 2020GLENMARK 01 JULY 2020 SHORT-SELL 2/3 LOT OF GLENMARK @ 430 Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives. Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies. Kindly message me for profit making signals and trades. Dear traders kindly follow our signals for maximum profits, our signals are based on analytics, algorithms, mathematical derivatives. Always be a responsible trader, kindly trade only when you have maximum opportunity in the market with minimum risk and with keynotes like data,analysis and proper strategies. Kindly message me for profit making signals and trades.
NSE:GLENMARKShort
by krishnakanth_kk
1
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended down.My A.I.dvisor found 426 similar cases when NKTR's price went up 15% within three months. In 218 out of those 426 cases, NKTR's price went down during the following month. Based on these historical data, my A.I. thinks the odds of an Uptrend reversal for NKTR are 51%.
NASDAQ:NKTRLong
by tickeronAI
1
VRTX - UP and Up and UPHi traders, I have picked another market for today´s analysis. Our best shot for today can be VRTX (we just have to wait for the entry bar). It´s a pharmaceutical company that increased the price of its stock during the Coronavirus crisis. If we compare the price with the SPY market and take the correlation into the consideration we can see that VRTX has more power to the upside than the whole Stock Market (SPY). Correlation - negative or positive - is an important part of portfolio management. If you are LONG in 100 markets that correlates closely to the SPY, it´s almost the same as opening one big position in the SPY market. Be careful! Good trading. Jakub FINEIGHT
AMEX:SPYLong
by Fineight
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again. But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in. Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NYSE:MRKLong
by ChristopherCarrollSmith
3
BMY at volume support with strong fundamentalsBristol Myers-Squibb got another FDA approval yesterday to expand the label for its immunotherapy drug Opdivo. The approval isn't a huge deal, but it would have been an upward catalyst on a normal stock market day. BMY remains a highly rated stock by analysts, at just 10 forward P/E, 1.17 PEG, and 3% dividend yield. One drawback of BMY is that it has a -1.5% ESP prediction from Zacks, which means its slightly more likely than average to miss its next earnings forecast. I also think we're likely to see some negative sentiment on pharmaceuticals as the Democrats show strength at the polls. My trading plan for BMY is to buy some here, and then triple my position at the $51 volume support node.
NYSE:BMYLong
by ChristopherCarrollSmith
Pfizer Shizer; Do the Bears Have this One? 🏥 | PFIZER ($PFE)🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments. Resources: www.jpost.com + www.marketwatch.com + www.barrons.com ✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- 1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe. 2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines). 3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio. 4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside. 5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside. Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up. Until then, good luck bears!
NYSE:PFE
by AlphaBotSystem
1
ABBV an Entry Point into the Wild World of BiotechBiotechnology and pharmaceutical companies have been quickly cycling through overbought and oversold. The problem has been so problematic that Sorrento Therapeutics had to specifically claim they were not a “pump and dump” scheme. Any whisper of a "cure" for Covid-19 has investors rushing to the entrance and quickly fleeing after results are what they had expected (an image of people rushing toward the exit and getting stuck in door comes to my mind). People who know the biotech sector have been cautiously watching the spectacle and trying to avoid getting trampled in a stampede. To be clear: your average investor is getting burned in the vaccine-hunt game. AbbVie "ABBV" is (and has been) a reliable pharmaceutical and biotechnology company for some time. The company is known for its generous dividend – previously at a yield of 5.20%. The company has a robust balance sheet with a Quick Ratio of 3.03 and a Current Ratio of 3.14. In the world of biotech, research and development is everything. ABBV pipeline is stacked with potential drug candidates many of which are in Phase 3 of development according to AbbVie’s investor relations brochure. From a technical analysis standpoint, the moving averages appear to be moving toward a positive crossover – EMA10 = 91.00, EMA20 = 90.88 EMA25 = 90.87. The stock does not look overbought or oversold according to the Stoch RSI and Money Flow Indicator. However, the MACD indicator shows that there may be a further swing downward before moving into positive territory. Finally, the linear regression model is one of the few biotechnology companies that is not inverse or appears caught in a sideway pattern. LONG ABBV purchased today (06-02-2020) @ 90.86.
NYSE:ABBVLong
by luminaryfi
6
QLGN - RTTR Merger - Soon to Bounce +30-85% Once it DoesAll, I think we are coming to a double bottom soon. The weekly on QLGN it's obvious there was a massive double top + merger made it sail down. The Question here is where does it end? It is essentially down over 45%. It is going to hit that trend line coming down and most likely fail if you want to swing that. Overall it will recover just a matter of how long. ** DISCLAIMER: If one of there pipeline news comes out thats positive this went down so fast that it will skyrocket on news. So pay attention** Levels I would look at at buy ins Possible bounce now. $5.80 $5.30 Alerts at buy in levels ALSO alerts above current level like 5-10% starting now. that way you get alerted if it does start to take off. Remeber to use volume and make sure it's actually breaking out or has news. Not just some pump on a lower timeframe. Wait for a daily candle. QLGN - RTTR Merger - Soon to Bounce
NASDAQ:QLGN
by DigitalData